Acknowledgements.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2011, v. 4, n. 6, p. 409, doi. 10.1177/1756285611426951
- Publication type:
- Article
Works matching IS 17562856 AND DT 2011 AND VI 4 AND IP 6
Results: 6
1
2
Registries, research, and regrets: is the FDA’s post-marketing REMS process not adequately protecting patients?
- Published in:
- Therapeutic Advances in Neurological Disorders, 2011, v. 4, n. 6, p. 339, doi. 10.1177/1756285611424461
- By:
- Publication type:
- Article
3
Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2011, v. 4, n. 6, p. 349, doi. 10.1177/1756285611423560
- By:
- Publication type:
- Article
4
The cognitive impact of antiepileptic drugs.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2011, v. 4, n. 6, p. 385, doi. 10.1177/1756285611417920
- By:
- Publication type:
- Article
5
Natural toxins implicated in the development of Parkinson’s disease.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2011, v. 4, n. 6, p. 361, doi. 10.1177/1756285611413004
- By:
- Publication type:
- Article
6
Management of sexual dysfunction in Parkinson’s disease.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2011, v. 4, n. 6, p. 375, doi. 10.1177/1756285611411504
- By:
- Publication type:
- Article